In line with these considerations, data of the PORTEC-3 trial indicated that the combination of chemotherapy with radiotherapy showed no benefit compared to radiotherapy alone in adjuvant treatment of POLE-mutated cancer [16]. The gene discussed is POLE; the disease is cancer.